Once microalbuminuria is present, the rate of progression to end-stage renal disease can be delayed by inhibition of the renin– angiotensin system.6 There is evidence that the use of agents that block the renin–angiotensin–aldosterone system, notably angiotensin receptor antagonists, may provide cardiovascular protection to diabetic patients with microalbuminuria.